Oncolytic viruses: overcoming translational challenges
Jordi Martinez-Quintanilla,1 Ivan Seah,1 Melissa Chua,1,2 and Khalid Shah1,2,3
1Center for Stem Cell Therapeutics and Imaging and
2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
3Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Address correspondence to: Khalid Shah, Brigham and Women’s Hospital, Harvard Medical School, BTM 8016O, 60 Fenwood Road, Boston, Massachusetts 02115, USA. Phone: 857.307.5233; Email: kshah@bwh.harvard.edu.
Find articles by Martinez-Quintanilla, J. in: JCI | PubMed | Google Scholar
1Center for Stem Cell Therapeutics and Imaging and
2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
3Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Address correspondence to: Khalid Shah, Brigham and Women’s Hospital, Harvard Medical School, BTM 8016O, 60 Fenwood Road, Boston, Massachusetts 02115, USA. Phone: 857.307.5233; Email: kshah@bwh.harvard.edu.
Find articles by
Seah, I.
in:
JCI
|
PubMed
|
Google Scholar
|
1Center for Stem Cell Therapeutics and Imaging and
2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
3Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Address correspondence to: Khalid Shah, Brigham and Women’s Hospital, Harvard Medical School, BTM 8016O, 60 Fenwood Road, Boston, Massachusetts 02115, USA. Phone: 857.307.5233; Email: kshah@bwh.harvard.edu.
Find articles by Chua, M. in: JCI | PubMed | Google Scholar
1Center for Stem Cell Therapeutics and Imaging and
2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
3Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Address correspondence to: Khalid Shah, Brigham and Women’s Hospital, Harvard Medical School, BTM 8016O, 60 Fenwood Road, Boston, Massachusetts 02115, USA. Phone: 857.307.5233; Email: kshah@bwh.harvard.edu.
Find articles by Shah, K. in: JCI | PubMed | Google Scholar
First published March 4, 2019 - More info
J Clin Invest. 2019;129(4):1407–1418. https://doi.org/10.1172/JCI122287.
© 2019 American Society for Clinical Investigation
Oncolytic virotherapy (OVT) is a promising approach in which WT or engineered viruses selectively replicate and destroy tumor cells while sparing normal ones. In the last two decades, different oncolytic viruses (OVs) have been modified and tested in a number of preclinical studies, some of which have led to clinical trials in cancer patients. These clinical trials have revealed several critical limitations with regard to viral delivery, spread, resistance, and antiviral immunity. Here, we focus on promising research strategies that have been developed to overcome the aforementioned obstacles. Such strategies include engineering OVs to target a broad spectrum of tumor cells while evading the immune system, developing unique delivery mechanisms, combining other immunotherapeutic agents with OVT, and using clinically translatable mouse tumor models to potentially translate OVT more readily into clinical settings.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)